Clinical Trial

Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

Name: Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL — clinical trial record (NCT07493330)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-03-19.

Trial Details

NCT Number	NCT07493330
Lead Sponsor	Ruijin Hospital
Conditions	PTCL, Refractory
Enrollment	86 participants
Start Date	2026-03-23
Primary Completion	2029-12-12 (estimated)
Study Completion	2030-12-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-07